INTRODUCTION
============

The endogenous cannabinoid (endocannabinoid) system is a complex network of receptors, a variety of ligands, and a series of enzymes that are responsible for ligand synthesis and breakdown. Endocannabinoids and their receptors are involved in the regulation of numerous physiological processes including neurotransmission, pain perception, learning, memory, cardiovascular homeostasis, appetite, motor function, and the immune response (reviewed in [@B39]; [@B27]; [@B14]). There is accumulating evidence to suggest that endocannabinoids and their receptors play important roles in bone metabolism by regulating bone mass, bone loss, and bone cell function. This review summarizes *in vitro* and *in vivo* findings relating to the action of cannabinoid ligands in the skeleton.

THE SKELETAL ENDOCANNABINOID SYSTEM
===================================

CANNABINOID RECEPTOR LIGANDS IN BONE
------------------------------------

Cannabinoid receptor ligands can be classified into three groups based on their source of production; endogenous cannabinoids (endocannabinoids), phytocannabinoids, and synthetic cannabinoids. Two of the best characterized endocannabinoids are *N*-arachidonoylethanolamine (anandamide) and 2-arachidonoylglycerol (2-AG). The endocannabinoids anandamide and 2-AG are responsible for most pharmacological actions associated with cannabinoid receptors in mammalian cells (Reviewed in [@B61]). Anandamide and 2-AG are both derivatives of arachidonic acid and are produced from breakdown of glycerophospholipids in the cell membrane. Anandamide is synthesized from *N*-arachidonoyl phosphatidylethanolamine (NAPE) by the enzyme NAPE-phospholipase D (NAPE-PLD), whereas synthesis of 2-AG occurs through the action of phospholipase C (PLC) and the diacylglycerol lipases alpha and beta (DAGLα and DAGLβ) on membrane phospholipids ([@B16]; [@B48],[@B49]; [@B76]). Once formed, endocannabinoids are transported across cell membranes by passive diffusion or endocytosis (for extensive review, refer to [@B20]; [@B30]). Anandamide and 2-AG are highly expressed in the brain and are also detected in a number of peripheral tissues including heart, liver, kidney, testis, and blood ([@B18], [@B19]; [@B80]; [@B42]; [@B15]; [@B67]; [@B83]; [@B82]). Endocannabinoids have a short half life due to the fact that they are rapidly degraded by a variety of enzymes including fatty acid amide hydrolase (FAAH) and monoacylglycerol lipase (MGAL; [@B17]). It should be noted, however, that FAAH is not specific for cannabinoids and degrades many other lipid containing molecules ([@B3]).

There is evidence that the endocannabinoids 2-AG and anandamide are produced endogenously in the bone marrow and within the metabolically active trabecular compartment ([@B2]; [@B82]). A number of studies have shown that osteoblasts and osteoclasts are capable of producing anandamide and 2-AG in culture. [@B66] reported in abstract form that cultured osteoblast-like cells MC3T3-E1 and mouse osteoclasts produced 2-AG *in vitro* and that anandamide was produced by cultured osteoblasts but not osteoclasts. A recent study by the same group reported that the differentiation of human osteoclasts from monocytes is associated with a reduction in 2-AG levels and an increase in anandamide levels ([@B86]). [@B70] reported that cultured human osteoclasts produced 2-AG and detectable quantities of anandamide; levels of both cannabinoids increased when the cultures were treated with the FAAH inhibitor URB597. Taken together, these observations indicate that 2-AG and anandamide are probably produced locally within bone and by bone cells in culture. In a study by [@B65], neither 2-AG nor anandamide were detected in synovial fluid from normal subjects, but both endocannabinoids were detected in synovial fluid from patients with osteoarthritis (OA) and rheumatoid arthritis (RA). Interestingly 2-AG levels in this study were higher in patients with OA as compared with RA.

Cannabinoid receptors are also activated by plant derived cannabinoids termed phytocannabinoids. The *Cannabis sativa* plant contains a large number of phytocannabinoids such as Δ^9^-tetrahydrocannabinol (THC) which is an agonist at CB~1~ and CB~2~ receptors. It should be noted, however, that many phytocannabinoids such as cannabidiol bind weakly to cannabinoid receptors (reviewed by [@B52]). A large number of synthetic cannabinoids have also been prepared some of which such as CP55,940, JWH133, and HU308 act as agonists thereby mimicking the action of endocannabinoids at a number of targets ([@B61]). On the other hand, a variety of synthetic compounds including SR141716A (also known as Rimonabant), AM251, and AM630 are described as inverse agonists/antagonists due to their ability to down-regulate the activity of cannabinoid receptors in the presence and absence of agonist binding ([@B22], [@B23]; [@B6]; [@B32],[@B33]; [@B44]; [@B43]; [@B69]; [@B53]). For a comprehensive list of pharmacological properties of some of the most important cannabinoid receptor ligands refer to ([@B61], [@B63]).

CANNABINOID RECEPTORS IN BONE
-----------------------------

Endocannabinoids and their synthetic analogs bind to and activate two known cannabinoid receptors: CB~1~ and CB~2~ ([@B47]; [@B64]). Recent studies suggest that the "orphan" G protein-coupled receptor GPR55 might represent a third cannabinoid receptor ([@B4]; [@B71]). The CB~1~ receptor, encoded by the *CNR1* gene was the first cannabinoid receptor to be identified and it's mainly expressed in the brain ([@B51]). In the skeleton, CB~1~ receptors are expressed on nerve fibers intervening bone ([@B81], [@B82]) and on cells of the immune system within the BM compartment ([@B39], [@B40]). We and others reported that CB~1~ receptors are also present on osteoblasts, osteoclasts, and BM derived adipocytes at both protein and mRNA levels ([@B34]; [@B70]). The CB~2~ receptor encoded by the *CNR2* gene was originally identified in macrophages in the marginal zone of the spleen ([@B55]) but is now known to be expressed in many other tissues including bone and synovial joints as well as some regions of the central nervous system ([@B8]; [@B21]; [@B60]; [@B56]; [@B40]; [@B36]; [@B58]; [@B75]; [@B59]). CB~2~ receptors are also expressed by osteoblasts, osteoclasts, and osteocytes at significantly higher level than that reported for CB~1~ ([@B36]; [@B58]; [@B70]; [@B86]). Recent studies reported that bone cells including osteoblasts and osteoclasts also express GPR55 which is known to be targeted by endocannabinoids and synthetic cannabinoid ligands ([@B77]; [@B73]; [@B1]; [@B70]; [@B87]). The GPR55 receptor encoded by the *GRP55* gene is widely expressed but the highest levels are detected in the adrenals, the gastrointestinal tract, and the brain ([@B71]). It should be noted that cannabinoids such as anandamide can bind to other receptors such as nicotinic acetylcholine receptors, calcium channels, voltage-gated potassium channels, and transient receptor potential vanilloid receptors (TRPVs; [@B15]; [@B84]), although the physiological significance of this in the skeleton is unclear.

CANNABINOID RECEPTOR SIGNALING IN BONE
--------------------------------------

Cannabinoid receptors are a class of cell membrane receptors that belongs to the G protein-coupled receptor superfamily ([@B7]; [@B69]). The CB~1~ receptor is constitutively active and therefore is able to transduce a biological signal in the absence of ligand ([@B9]). Accordingly, cannabinoid receptor agonists inhibit adenylyl cyclase causing reduction in intracellular levels of cyclic adenosine monophosphate (cAMP; [@B12]). CB~1~ and CB~2~ receptors are also linked to a variety of other second messengers including nuclear factor of kappa B (NFκB), p38 mitogen-activated protein kinase (MAPK), extracellular signal-regulated kinases (ERKs), c-Jun N-terminal kinases (JNKs), PI3/Akt and focal adhesion kinase (FAK) phosphorylation ([@B13]; [@B11]; [@B29]; [@B31]; [@B54]; [@B72]; [@B38]; [@B12]). The CB~1~ receptor has also been shown to couple to generation of the lipid second messenger ceramide by sphingomyelin hydrolysis and through *de novo* synthesis of ceramide ([@B28]). Cannabinoid receptor antagonists/inverse agonists such as the CB~1~ selective AM251 and CB~2~ selective AM630 block the effects of cannabinoid receptor agonists as well as down-regulate the constitutive activity of cannabinoid receptors in the absence of agonist binding ([@B6], [@B5]). Very little is known about the signaling mechanisms used by cannabinoid receptors to influence bone cell activity. There is evidence that the CB~1~ receptor regulates osteoblast and adipocyte differentiation by modulating intracellular cAMP levels ([@B34]). Moreover, recent studies showed that CB~2~ selective agonists induce mitogenic effects in osteoblasts via activation of a Gi protein-cyclin D1 and ERK1/2 axis ([@B57]; [@B78]). However, the mechanisms by which the CB~1~ and CB~2~ receptor regulate osteoclast differentiation and activity have not yet been fully clarified.

The GPR55 receptor is coupled to the G~12~ family of proteins (Gα~12~ and Gα~13~) rather than the G~i/o~ proteins. The signaling pathways downstream of GPR55 have been less widely studied than CB~1~ and CB~2~ but ligand-induced activation of GPR55 has been shown to activate the small GTP binding proteins RhoA, Cdc42, and Rac1 ([@B71]), to trigger activation of the ERK/MAPK signaling cascade ([@B37]); to elicit release of intracellular calcium through activation of PLC ([@B45]; [@B37]) and to activate NFAT through effects on intracellular calcium ([@B68]). Activation of GPR55 with O-1602 and lysophosphatidylinositol (LPI) in osteoclasts has been reported to increase levels of active GTP-bound Rho and to stimulate ERK phosphorylation ([@B87]).

REGULATION OF OSTEOCLASTIC BONE RESORPTION BY CANNABINOIDS
==========================================================

The *classical* cannabinoid receptors CB~1~ and CB~2~ and the *orphan* receptor GPR55 all play significant roles in the regulation of osteoclast function and bone resorption. [@B36] were first to report that genetic inactivation of the CB~1~ receptor results in high peak bone mass in young mice. In this study, a detailed micro-computed tomography scanning of bone and histomorphometric analysis of bone formation and resorption revealed that mice deficient in CB~1~ receptor have less osteoclasts and reduced bone resorption ([@B36]). These findings have led to the realization that cannabinoid receptors play a significant role in the regulation of peak bone mass. In keeping with these observations, the CB~1~ selective antagonist/inverse agonists AM251 and SR141716A have been reported to cause osteoclast apoptosis and inhibit osteoclast formation *in vitro* and osteoclasts cultured from CB~1~ deficient mice were found to be resistant to the effects of AM251 indicating that the mechanism of osteoclast inhibition was mediated at least in part, by the CB~1~ receptor ([@B36]). Further studies have shown that the CB~1~ selective antagonist/inverse agonist AM251 (1--3mg/kg/day) prevents ovariectomy induce bone loss in wild type mice and that CB~1~ deficient mice are resistant to ovariectomy-induced bone loss, findings which support the view that activation of the CB~1~ receptor promotes osteoclast differentiation and bone resorption ([@B36]). There is evidence that the defect in osteoclast formation in CB~1~ deficient mice is caused both, by a reduction in the sensitivity of osteoclast precursors to RANKL and a reduction in the ability of CB~1~ deficient osteoblasts to support osteoclast formation due to reduced RANKL expression ([@B34]).

The CB~2~ receptor also regulates osteoclast activity and bone resorption, but research in this area to date has yielded rather contradictory results. [@B58] reported that CB~2~ deficient mice developed osteoporosis with increasing age due to increased bone turnover. In keeping with these findings it was reported in the same study that the CB~2~ selective agonist HU308 inhibited RANKL-induced osteoclast formation in bone marrow and RAW 264.7 cultures*in vitro*. In complete contrast to these findings, Idris and colleagues reported, that anandamide and 2-AG, HU308 and JWH133 enhanced M-CSF- and RANKL-induced osteoclast formation over the concentration range 1--1000 nM ([@B36]), whereas the CB~2~ selective antagonist/inverse agonist AM630 was inhibitory ([@B36], [@B35]). Further studies by [@B35] showed that bone marrow cells isolated from CB~2~ deficient mice produce fewer osteoclasts in response to RANKL than wild type controls and that CB~2~ deficient mice were partially protected from ovariectomy-induced bone loss as compared with wild type littermates. In agreement with these observations others have reported that the endocannabinoids 2-AG and anandamide were found to stimulate bone resorption by human osteoclasts *in vitro* ([@B66]; [@B86]). [@B74] have recently introduced a new class of highly CB~2~ selective ligands that strongly inhibited RANKL stimulated osteoclastogenesis in murine and human cultures. In the same study, the authors went to demonstrate that endocannabinoids stimulate osteoclast formation and these effects were significantly inhibited by natural biphenyl neolignan derivatives ([@B74]). *In vivo*, [@B35] showed that the CB~2~ selective antagonist/inverse agonist AM630 prevents from ovariectomy-induced bone loss in a CB~2~ dependent and independent manner depending on administered dose. In broad agreement with this, [@B24] showed that AM630 protected against the development of titanium particle induced osteolytic bone loss by reducing osteoclastogenesis. Furthermore, [@B46] reported that the novel CB~2~ selective antagonist Sch.036 prevented bone damage in arthritic mice. Taken together these studies indicate that pharmacological inhibition of the CB~2~ receptor inhibits osteoclast formation and reduces bone loss in adult mice. However, [@B70] reported that the CB~2~ selective antagonist/inverse agonist AM630 at high concentrations (10 µM) stimulated human osteoclast formation. The stimulatory effects of AM630 on osteoclast formation in human cultures reported by Rossi and colleagues are exactly opposite to the inhibitory effects if AM630 on osteoclast formation in mouse cultures reported by [@B36], [@B35]. The reasons for this are unclear but possibilities include; species differences in responsiveness to AM630, off-target effects of AM630 at the high concentrations that were used or factors such as the choice of serum, some of which contain bioactive amounts of the endocannabinoid 2-AG sufficient to influence osteoclast differentiation and activity ([@B50]).

Recent studies have shown that the GPR55 receptor regulates osteoclast activity and bone resorption. A study by [@B87] showed that the GPR55 agonists [L]{.smallcaps}-α-LPI and O-1602 both inhibited osteoclast formation from bone marrow macrophages *in vitro*, whereas the GPR55 antagonist cannabidiol increased osteoclast formation. Although GPR55 agonists were found in this study to inhibit osteoclast formation, they actually stimulated the resorptive activity of osteoclasts. Conversely, the GPR55 antagonist cannabidiol enhanced osteoclast formation and inhibited resorptive activity. In keeping with these observations male mice with targeted inactivation of GPR55 were found to have increased numbers of osteoclasts*in vivo*, but these appeared unable to resorb bone effectively since trabecular bone mass was increased and cartilage remnants at the growth plate were not resorbed efficiently. Rather surprisingly, female mice deficient in GPR55 were found to have reduced numbers of osteoclasts and increased amounts of unresorbed growth plate cartilage, but had normal bone mass ([@B87]). Further studies in wild type mice revealed that cannabidiol reduced levels of CTX -- a biochemical marker of bone resorption -- consistent with the *in vitro* observations. Taken together these observations indicate that activation of GPR55 inhibits osteoclast formation, but increases the ability of osteoclasts to resorb bone. Conversely, inhibition of GPR55 appears to increase osteoclast formation but reduces the ability of osteoclasts to resorb bone. The cannabinoid derivative ajulemic acid (AJA) which is structurally similar to both CBD and THC has been found to inhibit formation of multinucleated TRAP positive cells in RANKL treated RAW264.7 cultures and in M-CSF and RANKL treated bone marrow macrophages ([@B25]). The mechanism by which AJA regulates osteoclast formation is unclear since it has weak affinity for CB~2~, and presumably does not activate CB~1~ in view of the fact that it lacks psychotropic properties. Possibilities would include an effect on PPARγ, which has recently been implicated in the regulation of osteoclast differentiation ([@B85]) or an effect on the GPR55 receptor.

In summary, there is evidence that both cannabinoid "*classical"* receptors CB~1~ and CB~2~ and the "*orphan"* receptor GPR55 regulate osteoclast activity and bone resorption. Conflicting results have been reported with regard to the role of CB~2~ in regulating osteoclast differentiation *in vitro* with stimulatory effects reported by some workers and inhibitory effects by others. The reasons for these differences remain unclear at present but one explanation may be the fact that many cannabinoid receptor ligands have complex pharmacology and are not entirely specific for the cannabinoid receptors they were originally designed to target. For example, AM251, which was classically considered to be specific CB~1~ selective antagonist/inverse agonist has recently been reported to act as a GPR55 agonist ([@B45]; [@B68]). Perplexingly SR141716A has been reported to act as a GPR55 antagonist ([@B37]) or agonist ([@B45]), depending on the assay system used. Similarly, the synthetic cannabinoid agonist CP55,940 has been shown to be act as a GPR55 agonist/partial agonist and JWH015, formerly considered a specific CB~2~ agonist has been shown to be a GPR55 agonist ([@B37]). These data indicate that the interpretation of some ligand activities previously attributed to effects on the CB~1~ or CB~2~ receptors may have been confounded by effects on the GPR55 receptor. Further research will clearly be required to investigate these issues and to explore the relative roles that CB~1~, CB~2~, and GPR55 play in regulating osteoclast differentiation and function.

REGULATION OF OSTEOBLAST FUNCTION AND BONE FORMATION BY CANNABINOIDS
====================================================================

Endocannabinoids and their receptors are involved in the regulation of osteoblast differentiation and bone formation. Mice with targeted deletion of the CB~1~ receptor have been found to develop osteoporosis with increasing age due to reduced bone formation and accumulation of adipocytes in the bone marrow space ([@B34]). In these studies, bone marrow stromal cells from CB~1~ deficient mice had an increased capacity for adipocyte differentiation and a reduced capacity for osteoblast differentiation and these effects were reproduced by treatment of wild type cultures with the CB~1~ selective antagonist/inverse agonist AM251 ([@B34]). Furthermore, the CB~1~ selective antagonist/inverse agonist AM251 was found to block the stimulatory effect of CP55,490 on bone nodule formation *in vitro* ([@B34]). Signaling studies have shown that blockade of CB~1~ receptors with AM251 in osteoblast like cells and preadipocytes up-regulated cAMP, stimulated CREB phosphorylation, inhibited expression of the osteoblast-specific transcription factor RUNX2 and increased expression of the adipocyte-specific transcription factor PPARγ ([@B34]). Other research has shown that the CB~1~ receptor plays a key role in regulating the increased bone formation that accompanies traumatic brain injury (TBI). This was investigated by [@B82] who reported that the expected increase in bone formation following TBI was absent in CB~1~ deficient mice, but was present in wild type and CB~2~ deficient mice. In this study, [@B82] also reported that TBI induced bone formation in wild type mice was abolished by the beta adrenergic receptor agonist isoproterenol. This led the authors to speculate that CB~1~ receptors present on presynaptic nerve endings in bone might enhance bone formation by suppressing catecholamine release ([@B82]). Although this is a plausible hypothesis, the experiments conducted did not determine whether the effect of the CB~1~ receptor on bone formation was truly mediated by this sequence of events or not. Other studies by the same authors ([@B81])showed that bone formation rate and mineral apposition rate were reduced in young (9--12-week old) CB~1~ deficient mice on a CD1 background, again confirming that CB~1~ appears to play a key role in regulating bone formation. Recent findings have shown that the CB~1~ receptor plays a role in glucocorticoid-induced bone loss ([@B88]; [@B41]). CB~1~ blockage attenuated the deleterious actions of glucocorticoid treatment on osteoblast activity and bone formation, significantly reduced bone loss and abrogated marrow adiposity ([@B88]; [@B41]). Mechanistic studies revealed that CB~1~ regulates glucocorticoid-induced dysfunction in osteoblasts via activation of a number of pathways including PI3/Akt, MAPK and runt-related transcription factor 2 and peroxisome proliferator-activated receptor 2 ([@B88]; [@B41]).

The CB~2~ receptor also plays a role in regulating bone formation. The CB~2~ selective agonists HU308, JWH133, and JWH015 have all been shown to stimulate bone nodule formation in bone marrow stromal cell cultures *in vitro*, although similar effects have been observed with non-selective agonists including anandamide, 2-AG, CP55,940, and WIN 55,212 ([@B58]; [@B75]; [@B34]). A specific role for CB~2~ receptors in mediating these effects is supported by the fact that bone marrow stromal cells from CB~2~ deficient mice have a reduced capacity to differentiate into bone nodules when compared with those of wild type littermates. Although mice with targeted inactivation of CB~2~ have increased bone turnover, there is a relative defect in bone formation as evidenced by the fact that CB~2~ deficient mice develop age-related osteoporosis ([@B58]). This is consistent with a model whereby CB~2~ is required for maintenance of normal bone formation in high bone turnover states.

The role of the GPR55 receptor on bone formation has not been extensively studied, but [@B87] found no significant abnormalities in histomorphometric indices of bone formation in GPR55 knockout mice and also reported that the GPR55 agonist O-1602 had little effect on bone nodule formation in mouse calvarial osteoblast cultures. In view of this it seems unlikely that GPR55 plays a major role in regulating bone formation. Several phytocannabinoids including cannabidiol, cannabinol, cannabidivarin, THC, and tetrahydrocannabivarin (THCV) have been reported to stimulate bone nodule formation, collagen production, and alkaline phosphatase activity in cultures of bone marrow stromal cells ([@B75]). At the present time, however, it is unclear to what extent these compounds are acting through cannabinoid receptors or other molecular targets. For example the phytocannabinoid THCV which was found in the above study to promote bone nodule formation is known to act as an antagonist of CB~1~ and CB~2~ receptors, which would be expected to reduce bone formation, according to the studies that have been performed in genetically modified mice ([@B58]; [@B81]; [@B34]). In view of this it is clear that further research will be required to fully investigate the mechanisms by which these phytocannabinoids regulate bone cell activity.

In summary, current evidence suggests that both the CB~1~ and CB~2~ receptors play significant roles in regulating osteoblast differentiation and bone formation in response to TBI and ageing. The fact that CB~1~ knockout mice develop accumulation of marrow fat also suggests that the CB~1~ receptor regulates the age-related "switch" in differentiation potential of bone marrow stromal cells ([@B26]).

REGULATION OF BONE MASS BY CANNABINOID RECEPTORS
================================================

A number of genetic and pharmacological studies have reported that cannabinoid receptors regulate bone mass in health and disease. Mice with deletion of the CB~1~, CB~2~, and GPR55 receptors all exhibit abnormalities of bone mass although this is dependent to an extent, on background strain, gender and age. The first report of an abnormality in bone mass in relation to the endocannabinoid system came from the studies of Idris and colleagues who reported that female CB~1~ deficient mice on inbred (ABH) and outbred (CD1) backgrounds exhibited high peak bone mass affecting the trabecular compartment of bone ([@B36]). This was found to be due to a defect in osteoclastic bone resorption and in keeping with this, CB~1~ deficient mice were found to be resistant to ovariectomy induced bone loss ([@B36]). In a subsequent study, [@B34] demonstrated that the high peak bone mass in CB~1~ deficient mice was found in both genders, and went on to show that CB~1~ deficient mice developed marked trabecular osteoporosis with increasing age due to a defect in bone formation and accumulation of marrow fat. Remarkably, this age-related bone loss occurred despite the fact that osteoclastic bone resorption remained lower in CB~1~ deficient mice than in wild type littermates throughout life. In another study [@B81] confirmed that CB~1~ deficient mice on a CD1 background had high peak bone mass. Although this was observed in both genders, the difference was significant only for male mice. In stark contrast to these findings, CB~1~ deficient mice on a C57BL/6 background were found by [@B81] to have reduced peak bone mass when compared with wild type littermates. The molecular mechanisms for these differences remain to be fully explored but they are probably related to polymorphisms or mutations in genes that interact with cannabinoid receptors to regulate cellular responses in different mouse strains. Abnormalities of bone mass have also been described in CB~2~ deficient mice. The first report came from [@B58] who found no major abnormalities of bone mass in young (8-week old) mice, but found that by 51 weeks of age, the CB~2~ deficient mice had developed marked trabecular osteoporosis with cortical expansion. Histomorphometric examination showed evidence of high bone turnover indicating that the likely mechanisms of bone loss was relative uncoupling of bone resorption and bone formation ([@B58]). [@B35] also found that peak bone mass was relatively normal in CB~2~ deficient mice and recent studies have shown these mice develop age-related osteoporosis ([@B78]).

In a recent study, [@B79] have reported in an abstract form that combined deficiency of the CB~1~ and CB~2~ receptors enhances peak bone mass but increases age-related bone loss. At 3 months of age, female CD1 mice deficient in both CB~1~ and CB~2~ receptors had significantly higher peak bone mass than wild type controls due to a significant decrease in osteoclast number and activity. Interestingly, these differences in peak bone mass and bone resorption observed were quantitatively similar to those previously observed in single knockouts of CB~1~ ([@B36], [@B34]) and CB~2~ ([@B79]) in the same background. By 12 months of age female deficient in both CB~1~ and CB~2~ receptors had significantly lower trabecular bone mass and histomorphometric analysis showed that this was associated with a dramatic increase in bone marrow fat accumulation and a reduction in osteoblast numbers and bone formation rate compared to wild type controls of similar age. The differences in bone mass and bone cell activity that the authors observed in female deficient in both CB~1~ and CB~2~ receptors were quantitatively similar to those previously observed in single knockouts of CB~1~ but not CB~2~ ([@B34]). Altogether, these data indicate that combined CB~1~ and CB~2~ deficiency enhances peak bone mass by an effect on bone resorption but predisposes to age-related osteoporosis by promoting adipocyte differentiation at the expense of osteoblast differentiation in the bone marrow compartment. This study demonstrates that CB~1~ and CB~2~ have overlapping but distinctive roles in skeletal homeostasis and show that CB~1~ in particular plays a key role in regulating osteoblast and adipocyte differentiation in the bone marrow compartment. Mice with targeted inactivation of the GPR55 receptor have been reported to have high peak bone mass affecting the trabecular compartment of the tibia and femur, but interestingly this was only noted in male mice ([@B87]). The mechanism seemed to be impairment of bone resorption; although the reasons responsible for the gender difference in skeletal phenotype in these animals remains unclear at present.

FUTURE RESEARCH DIRECTIONS
==========================

There is a steadily growing body of evidence suggesting that the skeletal endocannabinoid system plays a significant role in regulating bone mass and bone turnover. Several outstanding questions remain unanswered however. One is to define the mechanisms by which endocannabinoid production in bone is regulated and specifically to determine if it is influenced by classical calcium regulating hormones, cytokines and mechanical loading. Further research is also required to fully define the signaling pathways used by these receptors to regulate bone cell activity. There is evidence to suggest that the CB~1~ receptor regulates osteoblast and adipocyte differentiation through a cAMP-mediated pathway but little is known about the mechanisms by which cannabinoids regulate osteoclast activity. There have been major discrepancies between different studies with regard to the effects of different cannabinoid receptor ligands on osteoclast differentiation and function. These remain to be completely resolved but some of the discrepancies between studies could be due to the fact that many cannabinoid receptor ligands which were previously thought to be specific for CB~1~ and/or CB~2~ have now been shown to have effects on GPR55 signaling ([@B37]; [@B62]; [@B68]). A further area of research which remains to be explored is to determine to what extent the CB~1~ receptor exerts its effects on the skeleton by a central (neuronal) or peripheral mechanism. This is clinically relevant since if the peripheral effects were predominant, it may be possible to develop agonists of CB~1~ that do not cross the blood brain barrier that could favorably influence bone formation without causing adverse psychotropic effects. The outcome of these studies will greatly enhance our understanding of the role of the skeletal endocannabinoid system in bone remodeling and encourage the development of new treatments for bone diseases based on targeting cannabinoid receptors.
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